Differential anti-proliferative actions of peroxisome proliferator-activated receptor-γ agonists in MCF-7 breast cancer cells

Biochemical Pharmacology

Volumn 72, Issue 5, 2006, Pages 530-540

  Kim, Ki Young ^a   Kim, Sung Soo ^a   Cheon, Hyae Gyeong ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Apoptosis; Breast cancer; Differentiation; KR 62980; PPAR ; PTEN; Rosiglitazone

Indexed keywords

1 (METHYLIMINO N OXY) 3 PHENYL 6 (3 PHENYLPROPOXY) 1H INDENE 2 CARBOXYLIC ACID ETHYL ESTER; BIOCHEMICAL MARKER; KR 62980; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; ROSIGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA PRIMERS; HUMANS; INDENES; MORPHOLINES; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; THIAZOLIDINEDIONES;

EID: 33746716146     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.05.009     Document Type: Article

References (26)

1. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc 23 (2003) 52-57
2. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., et al. Differential expression and activation of a family of murine peroxisome-proliferator-activated receptors. Proc Natl Acad Sci USA 91 (1994) 7355-7359
3. Niho N., Takahashi M., Shoji Y., Takeuchi Y., Matsubara S., Sugimura T., et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 94 (2003) 960-964
4. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276 (2001) 37731-37734
5. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 (1994) 1224-1234
6. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94 (1997) 237-241
7. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., et al. Combination of a potent 20-epi-vitamin D3 analogue (KH1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56 (1996) 3570-3576
8. Motomura W., Nagamine M., Tanno S., Sawamukai M., Takahashi N., Kohgo Y., et al. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol 39 (2004) 461-468
9. Han S., and Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314 (2004) 1093-1099
10. Kilgore M.W., Tate P.L., Pai S., Sengoku E., and Price T.M. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol Cell Endocrinol 129 (1997) 229-235
11. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1 (1998) 465-470
12. Ning K., Pei L., Liao M., Liu B., Zhang Y., Jiang W., et al. Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J Neurosci 24 (2004) 4052-4060
13. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
14. Tamura M., Gu J., Takino T., and Yamada K.M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59 (1999) 442-449
15. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., and Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11 (2001) 764-768
16. Gratton J.P., Morales-Ruiz M., Kureishi Y., Fulton D., Walsh K., and Sessa W.C. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 276 (2001) 30359-30365
17. Chen Y.X., Zhong X.Y., Qin Y.F., Bing W., and He L.Z. 15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J Gastroenterol 9 (2003) 2149-2153
18. Kubota T., Koshizuka K., Willamson E.A., Asou H., Said J.W., Holden S., et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58 (1999) 3344-3352
19. van Golen C.M., Schwab T.S., Ignatoski K.M., Ethier S.P., and Feldman E.L. PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell Growth Differ 12 (2001) 371-378
20. Weng L.P., Smith W.M., Dahia P.L., Ziebold U., Gil E., Lees J.A., et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59 (1999) 5808-5814
21. Lu J., Jiang C., Fontane S., and Thompson H.J. Ras may mediate mammary cancer promotion by high fat. Nutr Cancer 23 (1995) 283-290
22. Pizer E.S., Jackisch C., Wood F.D., Pasternack G.R., Davidson N.E., and Kuhajda F.P. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56 (1996) 2745-2747
23. Burgermeister E., Tencer L., and Liscovitch M. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22 (2003) 3888-3900
24. Scherer P.E., Lewis R.Y., Volonte D., Engelman J.A., Galbiati F., Couet J., et al. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 272 (1997) 29337-29346
25. Spiegelman B.M., Hu E., Kim J.B., and Brun R. PPAR gamma and the control of adipogenesis. Biochimie 79 (1997) 111-112
26. Zhu Y., Qi C., Jain S., LeBeau M.M., Espinosa R., Atkins G.B., et al. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 96 (1999) 10848-10853